Product Description
Telotristat is used in combination with another medication (a somatostatin analog [SSA] such as lanreotide, octreotide, pasinreotide) to control diarrhea caused by carcinoid tumors (slow-growing tumors that release natural substances that can cause symptoms like diarrhea) in patients with diarrhea not controlled by a somatostatin analog alone. Telotristat is in a class of medications called antidiarrheal agents. It works by blocking the formation of a certain natural substance in the body that is released by the carcinoid tumors and causes diarrhea. (Sourced from: https://medlineplus.gov/druginfo/meds/a617029.html)
Mechanisms of Action: TPH Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Canada | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: Diarrhea
Known Adverse Events: Depressive Disorder | Headache | Edema | Flatulence
Company: Lexicon
Company Location: THE WOODLANDS TX 77381
Company CEO: Lonnel Coats
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Adenocarcinoma|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IRB00105292 | P2 |
Active, not recruiting |
Pancreatic Cancer|Adenocarcinoma |
2023-10-26 |